From day 14 and onwards, the tumor volume in the Pan-HER group was significantly smaller (p < 0.05) than that of the control group or any of the groups receiving antibody mixtures targeting EGFR, HER2 or HER3 individually. The gene discussed is ERBB3; the disease is neoplasm.